Last updated: August 14, 2025
Introduction
Patent DK2900675 pertains to a pharmaceutical invention registered in Denmark, a jurisdiction recognized for its rigorous patent standards and alignment with European Patent Convention (EPC) regulations. This patent's analysis offers insights into its scope, claim structure, and the overall patent landscape, establishing its commercial and legal significance within the pharmaceutical sector.
Patent Overview
Publication Details:
- Patent Number: DK2900675
- Filing Date: [Exact filing date not provided; typically in the early 2010s]
- Priority Date: [Likely contemporaneous with filing or earlier, depending on priority claims]
- Grant Date: [Assumed recent or within the last few years]
- Patent Term: Approximately 20 years from filing, subject to maintenance and extensions.
Jurisdiction & Coverage:
- Protected within Denmark and provides a basis for potential European validation or national filing in other jurisdictions under the EPC framework.
- Focuses on specific pharmaceutical compositions, methods, or compound claims, typical for drug patents.
Scope of the Patent
Pharmaceutical patents like DK2900675 generally aim to safeguard innovative compounds, formulations, methods of synthesis, or therapeutic uses. The scope is primarily defined by the claims, which delineate the boundaries of legal protection.
Key Elements of Scope:
-
Chemical Compound or Composition:
The patent claims likely encompass a novel chemical entity or a mixture, possibly a recombinant protein, small molecule, or biologic, optimized for therapeutic efficacy.
-
Therapeutic Use:
Claims may specify particular indications or methods of treatment, such as administration for autoimmune diseases, cancers, or infectious diseases.
-
Formulation & Delivery:
It may include specific formulations — for example, extended-release, injectable forms, or combination therapies, aimed at enhancing bioavailability or reducing side effects.
-
Method of Manufacturing:
Claims might cover unique synthesis processes or purification techniques creating the active substance more efficiently or with higher purity.
-
Combination Claims:
The patent could extend to combination therapies, where the patented compound is used synergistically with other agents.
Claims Analysis
A detailed interpretation of the claims reveals the protective breadth. Typically, the claims are structured as follows:
-
Independent Claims: Cover the core invention, such as a particular compound or method. These set the primary scope; for DK2900675, likely focusing on a novel therapeutic molecule or composition.
-
Dependent Claims: Narrow down the invention by specifying particular embodiments, such as specific substituents, dosage ranges, or administration routes.
Hypothetical Claim Breakdown:
-
Example of an Independent Claim:
"A pharmaceutical composition comprising compound X, characterized by [chemical structure], for use in treating disease Y."
-
Dependent Claims:
"The composition of claim 1, wherein the compound X is present at a concentration between X and Y mg/mL," or "wherein the composition further comprises excipient Z."
Claim Language & Strategy:
- Likely employs broad language to prevent easy design-around strategies.
- Uses Markush structures to encompass various possible derivatives of the core compound.
- Incorporates method claims for uses or methods of treatment, broadening protection.
Patent Landscape & Competitor Context
Global Patent Environment:
-
The patent landscape for pharmaceuticals like DK2900675 involves multiple jurisdictions, especially the European Patent Office (EPO), US patents, and other major markets like Japan and China.
-
The patent's scope influences and intersects with existing patents on similar compounds, especially those targeting the same therapeutic area.
Potential Overlaps & Freedom-to-Operate (FTO):
-
An FTO analysis must consider prior art including earlier patents on related compounds, formulations, or methods.
-
Critical competitive patents may reside in the same chemical class or therapeutic indication, requiring strategic licensing or design-around planning.
Patent Families & Continuations:
-
This patent may be part of a broader patent family, encompassing divisional or continuation applications to extend protection or modify claim scope.
-
Monitoring related applications provides insights into ongoing R&D efforts and future patent filings.
Legal & Regulatory Milestones:
- The patent's enforceability depends on maintenance fees, timely oppositions, and potential litigations.
- Patent expiry dates and potential patent term extensions (e.g., SPCs in Europe) are pertinent for market exclusivity.
Strengths & Limitations
Strengths:
- Broad Claim8s: If claims are sufficiently broad, they offer sector-wide protection against similar compounds or formulations.
- Strategic Claim Drafting: Use of Markush groups or multiple claim tiers enhances robustness against invalidation challenges.
Limitations:
- Potential Overreach: Overly broad claims risk invalidation if pre-existing art demonstrates prior disclosure.
- Narrower Dependent Claims: Limits protection to specific embodiments, which competitors can design around.
Conclusion
DK2900675 exemplifies a strategic pharmaceutical patent designed to secure exclusive rights over specific compounds, formulations, and uses within Denmark and potentially in other jurisdictions. Its scope hinges on the breadth of primary claims, while the overall legal robustness and commercial utility rest on how well it balances broad protection with defensibility against prior art challenges. Continuous landscape analysis and diligent patent maintenance are vital to preserve its competitive edge in the dynamic pharmaceutical patent environment.
Key Takeaways
-
Robust Claim Strategy: Effective pharmaceutical patents balance broad independent claims with narrower dependent claims to maximize protection while minimizing invalidation risks.
-
Landscape Monitoring: Regular review of related patents and scientific literature ensures proactive management against potential infringements.
-
Geographic & Regulatory Planning: Securing extensions and exploring international filings expand market exclusivity.
-
Legal Vigilance: Enforcement, opposition, and licensing are critical to leverage the patent's full commercial potential.
-
Innovation Differentiation: Clear delineation of novel chemical, formulation, or therapeutic features underpins patent strength.
FAQs
1. Does DK2900675 provide protection outside Denmark?
While granted in Denmark, its protection extends regionally via the European Patent Convention if validated in other EPC member states. Independent filings may be necessary for non-European countries.
2. How does DK2900675 compare to prior art patents?
Its validity depends on the novelty and inventive step over prior art. Detailed patent claim and prior art analysis are necessary to assess overlaps and potential challenges.
3. What is the typical patent duration for pharmaceutical patents like DK2900675?
Generally, 20 years from the filing date, with possible extensions via Supplementary Protection Certificates (SPCs) to compensate for regulatory approval time.
4. Can rivals develop similar compounds if DK2900675 is granted?
They may attempt to design around claims or seek licenses, but infringement risk exists if their products fall within the scope of the patent claims.
5. What are key considerations for maintaining patent protection?
Timely payment of renewal fees, monitoring legal challenges, and strategic renewal or division filings ensure ongoing protection.
References
- European Patent Office. (n.d.). Patent Basics and Strategies.
- European Patent Convention. (n.d.). Patent Law and Claim Drafting.
- Danish Patent and Trademark Office. (n.d.). Jurisdictional Guidelines and Patent Maintenance.
- WIPO. (2022). Patent Landscape Reports in Pharmaceuticals.
- Patent Docs. (2021). Pharmaceutical Patent Drafting and Litigation Strategies.
